W‘ALK’ Into the Next Stage

Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non–small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting. Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much about ALK-rearranged NSCLC; however, is it enough? Several concerns, such as the optimal sequence of ALKis, significance of antiangiogenic therapy, immune checkpoint therapy, and cytotoxic chemotherapy in ALK-rearranged NSCLC, should be clearly addressed, which would lead to the establishment of optimal treatment strategies and a more prolonged survival in patients with ALK rearrangement. Thus, we should w‘ALK’ into the next stage.

Original languageEnglish
Pages (from-to)122-126
Number of pages5
JournalClinical Lung Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
United States Food and Drug Administration
Therapeutics
anaplastic lymphoma kinase
Lung Neoplasms
Neoplasm Metastasis
Drug Therapy
Survival
Brain

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Toyokawa, G., Seto, T., Takenoyama, M., & Ichinose, Y. (2017). W‘ALK’ Into the Next Stage. Clinical Lung Cancer, 18(2), 122-126. https://doi.org/10.1016/j.cllc.2016.10.005

W‘ALK’ Into the Next Stage. / Toyokawa, Gouji; Seto, Takashi; Takenoyama, Mitsuhiro; Ichinose, Yukito.

In: Clinical Lung Cancer, Vol. 18, No. 2, 01.03.2017, p. 122-126.

Research output: Contribution to journalReview article

Toyokawa, G, Seto, T, Takenoyama, M & Ichinose, Y 2017, 'W‘ALK’ Into the Next Stage', Clinical Lung Cancer, vol. 18, no. 2, pp. 122-126. https://doi.org/10.1016/j.cllc.2016.10.005
Toyokawa G, Seto T, Takenoyama M, Ichinose Y. W‘ALK’ Into the Next Stage. Clinical Lung Cancer. 2017 Mar 1;18(2):122-126. https://doi.org/10.1016/j.cllc.2016.10.005
Toyokawa, Gouji ; Seto, Takashi ; Takenoyama, Mitsuhiro ; Ichinose, Yukito. / W‘ALK’ Into the Next Stage. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 2. pp. 122-126.
@article{d5e148cf47c24df19bb1ba54ee4765cb,
title = "W‘ALK’ Into the Next Stage",
abstract = "In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non–small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting. Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much about ALK-rearranged NSCLC; however, is it enough? Several concerns, such as the optimal sequence of ALKis, significance of antiangiogenic therapy, immune checkpoint therapy, and cytotoxic chemotherapy in ALK-rearranged NSCLC, should be clearly addressed, which would lead to the establishment of optimal treatment strategies and a more prolonged survival in patients with ALK rearrangement. Thus, we should w‘ALK’ into the next stage.",
author = "Gouji Toyokawa and Takashi Seto and Mitsuhiro Takenoyama and Yukito Ichinose",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.cllc.2016.10.005",
language = "English",
volume = "18",
pages = "122--126",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - W‘ALK’ Into the Next Stage

AU - Toyokawa, Gouji

AU - Seto, Takashi

AU - Takenoyama, Mitsuhiro

AU - Ichinose, Yukito

PY - 2017/3/1

Y1 - 2017/3/1

N2 - In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non–small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting. Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much about ALK-rearranged NSCLC; however, is it enough? Several concerns, such as the optimal sequence of ALKis, significance of antiangiogenic therapy, immune checkpoint therapy, and cytotoxic chemotherapy in ALK-rearranged NSCLC, should be clearly addressed, which would lead to the establishment of optimal treatment strategies and a more prolonged survival in patients with ALK rearrangement. Thus, we should w‘ALK’ into the next stage.

AB - In 2007, the rearrangement of anaplastic lymphoma kinase (ALK) was identified to be associated with the pathogenesis of a subset of patients with non–small-cell lung cancer (NSCLC). Surprisingly, approximately 4 years after the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-rearranged NSCLC by the US Food and Drug Administration. Subsequently, next-generation ALKis, such as alectinib and ceritinib, have been developed, and some of them have been applied in the clinical setting. Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much about ALK-rearranged NSCLC; however, is it enough? Several concerns, such as the optimal sequence of ALKis, significance of antiangiogenic therapy, immune checkpoint therapy, and cytotoxic chemotherapy in ALK-rearranged NSCLC, should be clearly addressed, which would lead to the establishment of optimal treatment strategies and a more prolonged survival in patients with ALK rearrangement. Thus, we should w‘ALK’ into the next stage.

UR - http://www.scopus.com/inward/record.url?scp=85006829877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006829877&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.10.005

DO - 10.1016/j.cllc.2016.10.005

M3 - Review article

C2 - 27865624

AN - SCOPUS:85006829877

VL - 18

SP - 122

EP - 126

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -